← All organizations

Xcovery

For profitContributed to NMEWebsite ↗

Also known as: XCOVERY | Xcovery Holding Company, LLC | Xcovery Holdings, INC

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

First NDA

Last known activity

Dec 18, 2024

Timeline

2000s

Jun 1, 2005
Xcovery— Founded

2020s

Dec 18, 2024
ensartinib— NDA Organization

Drugs by trial phase (8 distinct, 10 trials)

Phase 3 (2 own, 0 via acquisition)

Phase 2 (5 own, 0 via acquisition)

Phase 1 (1 own, 0 via acquisition)

pembrolizumab

Indications

Studied for

Marketed drugs (1)

ensartinib

Recent trials (12)

NCT04146571Lead sponsorN/A—
NCT05393466Study directorPhase 1/Phase 2Jul 1, 2023
NCT05393466Lead sponsorPhase 1/Phase 2Jul 1, 2023
NCT05665283Lead sponsorPhase 1Jan 1, 2023
NCT05665283Overall official - principal investigatorPhase 1Jan 1, 2023
NCT04373369CollaboratorPhase 2Jul 1, 2020
NCT03511222CollaboratorPhase 1Sep 11, 2018
NCT03583086CollaboratorPhase 1/Phase 2Jul 10, 2018
NCT03420508CollaboratorPhase 2Jan 10, 2018
NCT02898116CollaboratorPhase 1/Phase 2Mar 1, 2017
NCT02767804Lead sponsorPhase 3Jun 1, 2016
NCT01625234Lead sponsorPhase 1/Phase 2Jun 1, 2012

Details

Founded: West Palm Beach, FL, US Jun 1, 2005
First NDA: Dec 18, 2024
Last known activity: Dec 18, 2024